FoldRx Pharmaceuticals Garners $29,000,000 New Financing

  • Feed Type
  • Date
    6/15/2010
  • Company Name
    FoldRx Pharmaceuticals
  • Mailing Address
    100 Acorn Park Drive 5th Floor Cambridge, MA 02140
  • Company Description
    FoldRx is a leader in the discovery and development of first in class disease modifying drug therapies for diseases of protein misfolding and amyloidosis.
  • Website
    http://www.foldrx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $29,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    This financing is recognition of the strength of our tafamidis program and will allow us to continue advancing the development of tafamidis. We anticipate filing marketing applications in the second half of 2010.
  • M&A Terms
  • Venture Investor
    Novo A/S
  • Venture Investor
    Morgenthaler Ventures
  • Venture Investor
    HealthCare Ventures
  • Venture Investor
    Fidelity BioSciences
  • Venture Investor
    TPG Biotechnology Partners
  • Venture Investor
    Novartis Venture Fund
  • Venture Investor
    Alta Partners

By posting a comment, you agree to our terms and conditions.